BPC-157 oral vs injection: what the bioavailability data actually shows

The question, stated honestly

Type "bpc-157 oral" into any search bar and the first page is a wall of capsule listings, most sitting beside a banner claim that the pentadecapeptide "works orally because it was isolated from gastric juice." the implication: swallow the capsule, the peptide survives the stomach, absorbs into systemic circulation, and produces the same effects an abdominal injection would. that would be a remarkable claim if true, because oral bioavailability is the single hardest pharmacokinetic problem peptides face.

The literature is more interesting than either the marketing or the dismissive "peptides do not work orally" reflex. BPC-157 is genuinely unusual in gastric juice, and rat studies have dosed it in drinking water with measurable effects on the gut. but "unusual" is not "absorbed," and rat drinking-water effects are not "systemic bioavailability in an 80 kg human swallowing a 500 microgram capsule with breakfast." the gap between published data and consumer claims is worth walking through.

What BPC-157 actually is

BPC-157 is a synthetic 15-amino-acid peptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (one-letter: GEPPPGKPADDAGLV), molecular weight roughly 1419 daltons. the name comes from "body protection compound." the parent protein was isolated from human gastric juice by the Sikiric group at the University of Zagreb in the early 1990s, and BPC-157 itself was identified as the smallest active fragment they could synthesize and still see gastroprotective effects in their rat ulcer models.

Two structural details matter for the oral question. first, the sequence is unusually proline-heavy. four of the fifteen residues are proline, including a contiguous Pro-Pro-Pro triplet at positions 3 to 5. proline is the one proteinogenic amino acid whose side chain bonds back to its own backbone nitrogen, which constrains the peptide bond geometry and makes proline-rich stretches comparatively resistant to pepsin and most gastric peptidases. second, the sequence contains no aromatic residues (no Phe, Tyr, or Trp). pepsin preferentially cleaves at aromatic positions. a peptide bond made of mostly proline, glycine, and small aliphatic residues is, in pure bench-chemistry terms, a poor pepsin substrate.

None of this is controversial. it is also not, by itself, evidence of oral bioavailability. a peptide can be pepsin-resistant in a test tube and still fail to cross the intestinal epithelium, because gastric stability and absorption are two completely separate biological problems.

Side note: BPC-157 does not naturally exist as a 15-mer in your body

"BPC-157 was isolated from gastric juice" is true of the parent BPC protein. the synthetic 15-mer sold as BPC-157 is a designed fragment, not a free peptide demonstrated to occur in human tissue. the distinction matters when someone argues that swallowing it is "just eating what is already in your stomach."

The gastric stability claim, examined

The most-cited Sikiric line on oral viability is that BPC-157 remains intact in human gastric juice for more than 24 hours. this number appears in multiple review papers from the Zagreb group and is repeated almost verbatim in nearly every consumer product description. what the underlying experiment shows is more specific: synthetic BPC-157 incubated in aspirated human gastric juice at body temperature does not detectably degrade across a 24-hour window in the assay the authors used. this is informative. it is not, however, a measurement of how much intact peptide makes it past the proximal small intestine, where pancreatic proteases (trypsin, chymotrypsin, elastase, carboxypeptidases) and brush-border peptidases do most of the dietary protein digestion.

The published Sikiric literature does not provide a clean small-intestinal stability time course in dogs or humans. the rat oral-dose studies that follow infer functional activity from downstream endpoints (ulcer area, anastomosis breaking strength, transit time) without measuring plasma BPC-157 directly. so when a product page extrapolates from "stable in gastric juice for 24 hours" to "high oral bioavailability," it is stitching together three separate questions that the published work has only answered one of.

Where the rat oral data actually is strong

The place to take oral BPC-157 most seriously is the gut itself. the Sikiric program ran a long series of rat experiments using BPC-157 dissolved in drinking water, typically delivering roughly 10 micrograms per kilogram per day or 10 nanograms per kilogram per day (depending on the protocol) in approximately 12 ml of water per rat per day. across these studies the per-oral arm repeatedly matched the intraperitoneal arm on local gut endpoints:

• Cysteamine-induced duodenal ulcer: oral and intraperitoneal BPC-157 both reduced ulcer area relative to vehicle.
• Cysteamine and TNBS colitis: reductions in colon damage scores in both routes.
• Jejunoileal and esophagogastric anastomosis: increased breaking strength and pressure to leak in animals receiving oral or parenteral BPC-157 around the time of surgery.
• Short bowel syndrome after massive small bowel resection: oral BPC-157 over four weeks improved villus height, crypt depth, and weight recovery.
• Colocutaneous fistula in rats: the same PL-14736 (BPC-157) preparation that entered the human IBD trial healed externalized colon fistulas, with comparable outcomes between oral and parenteral arms.

This is a genuinely consistent body of evidence for one specific use case: local action on the gastrointestinal mucosa, in rats, when the peptide is delivered as a continuously available solution in drinking water. the steel-man for oral BPC-157 starts here, not at "high systemic bioavailability." the peptide does not need to absorb intact into the portal vein to act on the epithelium it is currently touching. this is the same logic that lets non-absorbable drugs like rifaximin or oral vancomycin work in the lumen without measurable plasma levels.

The local-action argument

If you accept the gut-mucosal evidence, the "local action" framing reframes the bioavailability debate. for a target tissue that is in direct contact with the oral dose, low systemic bioavailability is not a failure mode. it might even be the point. an antiulcer compound that stays in the lumen until it reaches its target, exerts paracrine effects on enterocytes and the submucosal microvasculature, and then gets cleaved into amino acids is a perfectly sensible pharmacology. the question is just whether you are using BPC-157 for that, or for something else.

The consumer market for BPC-157, however, is not primarily a gut market. the most common reasons people order capsules are tendon and joint pain, soft-tissue recovery, muscle injury, post-workout inflammation, and general "healing." for those indications, the target tissue is not the intestinal lumen. the peptide has to be absorbed intact (or as a still-bioactive metabolite), survive first-pass hepatic clearance, distribute through plasma to tendon, ligament, or skeletal muscle, and reach a concentration adequate to engage whatever VEGF-, nitric-oxide-, or growth-factor-mediated pathway is doing the work. none of those last steps have been demonstrated for orally dosed BPC-157 in any published pharmacokinetic study.

Animal pharmacokinetics: what we actually know

The most useful pharmacokinetic paper to date is the 2022 study by Xu and colleagues in Frontiers in Pharmacology, which characterized BPC-157 in rats and beagle dogs after intravenous and intramuscular dosing using tritium-labeled peptide and a validated LC-MS/MS assay. the headline numbers are sobering:

• Absolute intramuscular bioavailability: approximately 14 to 19 percent in rats, 45 to 51 percent in beagle dogs across the tested dose range.
• Plasma elimination half-life: under 30 minutes in both species.
• Time to peak (Tmax) after IM: 3 to 9 minutes.
• Plasma detectability: undetectable by 4 hours post-dose.
• Metabolic fate: rapid hydrolysis into smaller peptide fragments and ultimately free amino acids, which then enter the standard amino acid pool.

What is conspicuously absent from this paper is an oral arm. the authors did not report oral bioavailability, oral Tmax, or oral Cmax in either species. as of this writing in may 2026, there is no peer-reviewed pharmacokinetic study in any species that reports a measured plasma concentration after a swallowed dose of BPC-157. consumer pages that quote oral bioavailability numbers (commonly "3 percent" for acetate and "up to 90 percent" for arginate salt forms) are citing manufacturer technical sheets or formulation patents, not pharmacokinetic primary literature.

The honest evidence ceiling

The single most important sentence in any honest BPC-157 article is this one: there are no randomized controlled trials of BPC-157 in humans, by any route, for any indication, with full published primary efficacy data. the PL-14736 / PLD-116 program for ulcerative colitis in Croatia in the 2000s is referenced in dozens of review papers from the Sikiric group, often described as a completed Phase II showing efficacy and an excellent safety profile, but the standalone clinical trial publication that would let independent reviewers see endpoint data, drop-out rates, dosing schedules, and statistical analysis has never appeared in the peer-reviewed literature. that absence is the actual ceiling.

A 2025 systematic review in the American Journal of Sports Medicine on BPC-157 for orthopaedic applications screened 544 articles and found exactly one clinical study eligible for inclusion. the remaining 35 included papers were preclinical animal models. a handful of small open-label observational reports (a 16-patient knee pain series, a 12-patient interstitial cystitis bladder injection series, a 2-subject IV tolerability pilot at doses up to 20 mg) exist, but none use the oral route and none meet the standard for "evidence that swallowed BPC-157 produces the effects being marketed." if you are new to evaluating peptide claims and want a framework for how approved compounds differ from research-only ones, our beginner's decision guide to peptides places BPC-157 in the broader context of the three evidence tiers. and if you are deciding whether to purchase from a specific vendor, the peptide safety checker walks through what a real third-party test report should contain.

Evidence tier breakdown

A useful way to talk about BPC-157 oral is to separate the claim being made from the route, and ask which evidence tier each combination sits in. the tiers below match how the rest of our blog scores compounds.

• Tier 1 (regulatory approval): none, by any route, for any indication.
• Tier 2 (published RCT): none, by any route, for any indication.
• Tier 3 (open-label or pilot in humans): three small human reports, all parenteral or intralesional, none oral.
• Tier 4 (preclinical, oral, local gut indication): strong and consistent in rat models of ulcer, colitis, anastomosis, and short bowel syndrome.
• Tier 4 (preclinical, oral, systemic musculoskeletal or neurological indication): weak. the existing rat tendon, ligament, brain, and cardiovascular work overwhelmingly uses intraperitoneal, subcutaneous, or intramuscular routes, not per-oral.
• Tier 5 (anecdote / marketing): the entire consumer oral capsule market sits here. user testimonials are abundant but not gradable as evidence.

Route comparison: oral vs sublingual vs subcutaneous vs intramuscular

The table below summarizes how the four most common BPC-157 routes compare on the dimensions that actually matter when you are reading a product page. "evidence in humans" is uniformly weak across all routes; that row is not a typo.

The "stable gastric pentadecapeptide" framing vs consumer marketing

The academic literature uses the phrase "stable gastric pentadecapeptide BPC-157" to convey one specific property: pepsin resistance in aspirated gastric juice. it is descriptive, not promotional. in academic context the phrase appears alongside qualifications about route, dose, and the species being studied. a paper that calls BPC-157 a "stable gastric pentadecapeptide" in its title will, in its methods section, dose the rats intraperitoneally with a reconstituted solution.

Consumer marketing flattens this in three predictable ways. first, "stable in gastric juice" becomes "survives the entire GI tract," which is a much stronger claim that the source experiment does not make. second, "isolated from gastric juice" becomes "naturally present in your stomach," which conflates the parent BPC protein with the synthetic 15-mer. third, "oral dosing works in rat ulcer models" becomes "oral dosing is equivalent to injection for any indication," which fails on both the indication and the species step.

None of this means the oral form is useless. it means the gap between what the underlying paper says and what the product page says is large enough that you should not pay an injection-grade price for capsule-grade evidence, or vice versa.

Practical verdict: what this means if you are deciding

The literature points to a small set of straightforward conclusions.

1. If the target is the gut itself (reflux-like symptoms, post-surgical anastomosis recovery, suspected IBD-spectrum complaints, NSAID-associated gastric irritation), oral BPC-157 has the strongest preclinical case. the rat data is consistent and the local-action argument is mechanistically clean. this is also the only context in which the historical PL-14736 human program was conducted.
2. If the target is a tendon, ligament, joint, or muscle, the oral route has no published pharmacokinetic support. the entire rat tendon-healing literature uses parenteral dosing. choosing oral capsules for an Achilles or rotator-cuff issue is using a route with no measured systemic exposure to treat a tissue with no measured drug delivery. it is also worth knowing that tendons and muscles adapt to load at different rates -- our piece on why tendons lag muscles when training ramps up explains why the tissue you are trying to reach is already one of the slowest-recovering in the body, independent of any peptide.
3. If the target is anything systemic and "general" (longevity, "anti-inflammatory" background dosing, "mitochondrial support"), there is no published evidence that supports either route, but the parenteral route at least has a 14 to 51 percent absorption fraction to point at. the oral route does not.
4. Regardless of route, the human evidence ceiling is the same for all of them. there is no RCT. there is no regulatory approval. the World Anti-Doping Agency banned the compound in 2022, and the FDA placed bulk BPC-157 in its Category 2 list in 2023 (insufficient safety data to support compounding). that ceiling does not move based on whether you swallow, inject, or hold something under your tongue. for more on what the 2023-2026 FDA compounding changes mean for the broader peptide category, see our guide to the FDA category-2 reclassification.

If you are evaluating any source of BPC-157 (capsule, vial, lozenge), the supplier-quality questions are the same as for every other research peptide. we walk through certificate-of-analysis review, HPLC purity, and identity testing in our guide to vetting research peptides. if you are evaluating an injectable vial specifically, the math of mixing it correctly with bacteriostatic water is in the peptide reconstitution walkthrough, and the stability window after mixing is covered by the peptide storage calculator. for context on which compounds in the broader hypertrophy and recovery space have published human data versus rat data, see muscle building peptides: what the evidence shows.

What would actually change this answer

The published evidence base would meaningfully change in three ways, all of which are gateable on new primary research that no one has yet conducted publicly.

• A peer-reviewed pharmacokinetic study in dogs or humans that measures plasma BPC-157 concentration after an oral dose, with the assay validated against a parenteral arm in the same animals. this is the experiment that would either confirm or refute the systemic-absorption claim, and it is the most glaring missing piece.
• A head-to-head comparison of acetate and arginate salt forms in the same animal model with measured plasma levels, not extrapolated formulation theory.
• A properly published account of the PL-14736 Phase II ulcerative colitis program, with full patient counts, endpoints, dose schedule, and adverse-event tables. this is the single dataset that, if released, would move BPC-157 from "preclinical with anecdote" to "early human evidence, at least for one specific indication."

Until any of those exist, the most honest framing is the one this article opened with: oral BPC-157 has a real preclinical case for local gut effects in rats, a coherent mechanistic story for why it survives gastric juice, no measured systemic absorption data after a swallowed dose, and no human RCT for any route. everything else is extrapolation, branding, or anecdote.

Frequently asked, in one place

Does BPC-157 in a capsule reach my bloodstream?

No published pharmacokinetic study has measured plasma BPC-157 after an oral capsule dose in any species. specific oral bioavailability percentages (3 percent, 30 percent, 90 percent) are formulation marketing, not peer-reviewed measurement.

Is sublingual better than swallowing?

No head-to-head study compares the two. a 1419-dalton peptide is a poor candidate for oral mucosal transit on size grounds; sublingual claims rely on analogy to smaller peptides like vasopressin (1084 daltons), where buccal absorption is itself modest.

Is the oral form safe?

Rat oral data shows a clean acute toxicity profile across days to weeks. that is not the same as long-term human safety, and no meaningful human safety database for oral BPC-157 exists. the WADA 2022 ban reflects performance concerns, not a positive safety statement.

Summary in one paragraph

BPC-157 is pepsin-resistant in gastric juice because it is proline-rich and aromatic-free, which supports a coherent local-action argument for gut indications and matches rat drinking-water studies on ulcers, colitis, and anastomosis. it does not support the marketing claim that oral capsules deliver injection-equivalent systemic exposure: the published pharmacokinetic literature is intramuscular and intravenous only (14 to 51 percent absolute bioavailability, sub-30-minute plasma half-life), no oral pk study exists in any species, and no human RCT exists for any route. the route question is real, but it sits under a much bigger evidence-ceiling question.